Antimicrobial Susceptibility Testing Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Antimicrobial Susceptibility Testing Market

Antimicrobial Susceptibility Testing Market by Product (Manual, Automated), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion, Agar Diffusion, Genotyping), End User & Region - Global Forecasts to 2027

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 5931 Feb, 2023, by marketsandmarkets.com
purchase report REQUEST FREE CUSTOMIZATION Inquiry Before Buying

Updated on : March 01, 2023

The global antimicrobial susceptibility testing market in terms of revenue was estimated to be worth $3.6 billion in 2022 and is poised to reach $4.7 billion by 2027, growing at a CAGR of 5.5% from 2022 to 2027. The rising prevalence of infectious diseases, high antibiotic resistance, and supportive government attempts to lessen the burden of infectious diseases are all factors contributing to the growth of the antimicrobial susceptibility testing (AST) market. The use of antibiotic susceptibility testing is growing due to an increase in certain illnesses, such as bloodstream infections and pneumonia brought on by E. coli, K. pneumonia, and P. aeruginosa, among others.

Global Antimicrobial Susceptibiity Testing Market

Antimicrobial Susceptibility Testing Market

e- Estimated; p- Projected

To know about the assumptions considered for the study, Request for Free Sample Report

Antimicrobial Susceptibility Testing Market Dynamics

Drivers: Emergence of multidrug resistance due to drug abuse

As medication resistance increases internationally, making diseases harder to cure and ultimately to mortality, antibiotics are becoming less and less effective. According to the WHO priority pathogen list, new antibiotics are urgently needed, for instance, to treat carbapenem-resistant gram-negative bacterial infections. Unfortunately, these novel medicines will experience the same destiny as the present antibiotics and become useless if people do not modify the way antibiotics are used currently.

Opportunities: Growth opportunities in emerging market

Emerging countries such as APAC,India, China and Japan  present significant opportunities for players operating in the Antimicrobial susceptibiity testing market. The demand for Antimicrobial susceptibiity testing market in these countries is increasing owing to rapid growth in medical tourism, the growing adult (aged 20 and above) population, increasing drug abuse. These countries are also home to a strong and qualified workforce and have a great knowledge of advance technologies.Furthermore, these countries have lenient policies for imports/exports and are underpenetrated in most aspects, which could help companies in brand development. Increasing developing technicians and the keen to know about new technologies is helping the regions to grow and update their technologies.

Challenges: Complex Regulatory Frameworks

The time gap between defining clinical breakpoints, approving novel antimicrobial drugs, and putting these medicines on the market is one of the biggest problems with antimicrobial susceptibility testing. When pharmaceutical companies submit unapproved new medication applications, the FDA determines certain cutoff criteria. Adoption of antimicrobial susceptibility products is further constrained by the lack of clinical breakpoints for certain medications. For example, there are no clinical cutoffs available to determine antifungal treatment efficacy in invasive non-Aspergillus mold infections.

Restraints: High Cost of automated Laboratory Instruments

Automated antimicrobial laboratory equipment has top-of-the-line features and functions, and it costs a lot of money. The incubation and detection times are shortened by the use of automated AST systems. The high cost of maintenance for these devices, which are well-equipped with cutting-edge software that requires routine upkeep, is another hurdle to this industry.

By product type, the automated laboratory instruments segment accounted for the largest share during the forecast period.

In 2022, automated laboratory instruments accounted for the largest share of in the antimicrobial susceptibility testing market. This segment is projected to reach USD 1.5 billion by 2027  from USD 1.7 billion in 2022, at a CAGR of 6.9% during the forecast period.

By End, User Hospitals and diagnostic center is expected to grow at the fastest rate during the forecast period.

In 2022, hospitals and diagnostic centers holds a larger share In the antimicrobial susceptibility testing market with a share of 63.5%. This end-user segment is projected to reach USD 2.9 billion by 2027 from USD 2.2 billion in 2022, at a CAGR of 5.7% during the forecast period. This end-user segment is also expected to grow at the highest CAGR of 5.7% during the forecast period.

North America is expected to be the largest market during the forecast period.

The highest portion of the global market for antimicrobial susceptibility testing—35.4%—is accounted for by North America. US and Canada make up North America. The high frequency of illnesses for which pre-tests are required, the growing elderly population, and the appearance of novel bacterial, fungal, and viral strains in North America are the reasons why North America has the biggest proportion. Due to rising drug addiction, misuse, and non-compliance, the APAC area is developing at the highest CAGR of 6.7%.

Antimicrobial Susceptibility Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2021, prominent players in the market are include bioMérieux SA (France), Becton, Dickinson, and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US) among others.

Antimicrobial Susceptibility Testing Market Report Scope:

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Type, Method, Applications, End User, and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

Companies covered

include bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), HiMedia Laboratories (India), Liofilchem S.R.L Diagnostics (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd. (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US

This report has segmented the Antimicrobial susceptibiity testing market into following segments & sub-segments:

By Product

  • Manual Antimicrobial Susceptibility Testing Product
    • Susceptibility Testing Disks
    • Mic Strips
    • Susceptibility Plates
  • Automated Laboratory Instruments
  • Culture and Growth Media
  • Consumables

By Type

  • Antibacterial susceptibility testing
  • Antifungal susceptibility testing
  • Antiparasitic susceptibility testing
  • Other susceptibility testing

By Method

  • Etest Method
  • Disk Diffusion
  • Automated Susceptibility testing instruments
  • Agar Diffusion
  • Genotyping method

By Application

  • Clinical Diagnostics
  • Drug Discovery and development
  • Epidemiology
  • Other applications

By End User

  • Hospitals and Diagnostic centers
  • Pharmaceutical and Biotechnology Companies
  • Research &Academic Institutes
  • Clinical Research Organizations

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In Jan,2023 bioMerieux launched a automated instrument named MAESTRIA
  • In Aug,2022 BD India launched the BD MAX MDR-TB panel.
  • In May ,2022 Thermofisher scientific introduced automated antimicrobial susceptibility products.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 29)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 34)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
                    2.1.2.3 Breakdown of primaries
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 5 TOP-DOWN APPROACH
          FIGURE 6 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT 
          TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
    2.8 IMPACT OF RECESSION ON GLOBAL MARKET 
 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT,  2022 VS. 2027 (USD MILLION)
    FIGURE 9 GLOBAL MARKET SHARE, BY TYPE,  2022 VS. 2027
    FIGURE 10 GLOBAL MARKET, BY APPLICATION,  2022 VS. 2027 (USD MILLION)
    FIGURE 11 GLOBAL MARKET, BY METHOD,  2022 VS. 2027 (USD MILLION)
    FIGURE 12 GLOBAL MARKET SHARE, BY END USER,  2022 VS. 2027
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
 
4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 GLOBAL MARKET OVERVIEW 
          FIGURE 14 TECHNOLOGICAL ADVANCEMENTS AND RISING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    4.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 
          FIGURE 15 SUSCEPTIBILITY TESTING DISKS SEGMENT TO DOMINATE MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET
    4.3 NORTH AMERICA: MARKET, BY COUNTRY AND TYPE 
          FIGURE 16 ANTIBACTERIAL SUSCEPTIBILITY TESTING SEGMENT TO DOMINATE NORTH AMERICAN MARKET
    4.4 GEOGRAPHIC SNAPSHOT: KEY GROWTH OPPORTUNITIES IN GLOBAL MARKET 
          FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of infectious diseases coupled with epidemic and pandemic events
                    5.2.1.2 Increasing funding, research grants, and public-private investments
                    5.2.1.3 Technological advancements
                    5.2.1.4 Growing government initiatives to detect and control antimicrobial-resistant species
                    5.2.1.5 Emergence of multidrug resistance due to drug abuse
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of automated ID/AST systems
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Complex regulatory frameworks
    5.3 PORTER’S FIVE FORCES ANALYSIS 
           5.3.1 OVERVIEW
                    TABLE 2 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.2 THREAT OF NEW ENTRANTS
           5.3.3 THREAT OF SUBSTITUTES
           5.3.4 BARGAINING POWER OF SUPPLIERS
           5.3.5 BARGAINING POWER OF BUYERS
           5.3.6 INTENSITY OF COMPETITIVE RIVALRY
    5.4 REGULATORY ANALYSIS 
           5.4.1 NORTH AMERICA
                    5.4.1.1 US
                                TABLE 3 US FDA: MEDICAL DEVICE CLASSIFICATION
                                TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                    5.4.1.2 Canada
                                TABLE 5 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
           5.4.2 EUROPE
           5.4.3 ASIA PACIFIC
                    5.4.3.1 Japan
                                TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS AND MEDICAL DEVICES AGENCY
                    5.4.3.2 China
                                TABLE 7 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.4.3.3 India
    5.5 ECOSYSTEM ANALYSIS: GLOBAL MARKET 
          FIGURE 19 ECOSYSTEM COVERAGE
    5.6 VALUE CHAIN ANALYSIS 
           5.6.1 RESEARCH & DEVELOPMENT
           5.6.2 MANUFACTURING AND ASSEMBLY
           5.6.3 DISTRIBUTION, MARKETING AND SALES, AND POST-SALES SERVICES
                    FIGURE 20 GLOBAL MARKET: VALUE CHAIN ANALYSIS
    5.7 SUPPLY CHAIN ANALYSIS 
           5.7.1 PROMINENT COMPANIES
           5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES
                    FIGURE 21 SUPPLY CHAIN ANALYSIS
    5.8 KEY CONFERENCES AND EVENTS IN 2023–2024 
          TABLE 8 GLOBAL MARKET: DETAILED LIST OF MAJOR CONFERENCES AND EVENTS
    5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
                    TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
           5.9.2 BUYING CRITERIA
                    FIGURE 23 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
                    TABLE 10 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
    5.10 PATENT ANALYSIS 
           FIGURE 24 TOP 10 PATENT APPLICANTS
           FIGURE 25 TOP 10 PATENT OWNERS
 
6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT (Page No. - 77)
    6.1 INTRODUCTION 
          TABLE 11 GLOBAL MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
    6.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS 
          TABLE 12 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE,  2020–2027 (USD MILLION)
          TABLE 13 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.1 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE
                    TABLE 14 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE,  2020–2027 (USD MILLION)
           6.2.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION
                    TABLE 15 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY APPLICATION, 2020–2027 (USD MILLION)
           6.2.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD
                    TABLE 16 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD, 2020–2027 (USD MILLION)
           6.2.4 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER
                    TABLE 17 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
           6.2.5 SUSCEPTIBILITY TESTING DISKS
                    6.2.5.1 Significant adoption of disk diffusion tests in emerging countries to support segment growth
                                TABLE 18 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    6.2.5.2 Susceptibility testing disks market, by type
                                TABLE 19 SUSCEPTIBILITY TESTING DISKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    6.2.5.3 Susceptibility testing disks market, by application
                                TABLE 20 SUSCEPTIBILITY TESTING DISKS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    6.2.5.4 Susceptibility testing disks market, by method
                                TABLE 21 SUSCEPTIBILITY TESTING DISKS MARKET, BY METHOD, 2020–2027 (USD MILLION)
                    6.2.5.5 Susceptibility testing disks market, by end user
                                TABLE 22 SUSCEPTIBILITY TESTING DISKS MARKET, BY END USER, 2020–2027 (USD MILLION)
           6.2.6 MIC STRIPS
                    6.2.6.1 Growing adoption of broad-spectrum MIC strips to support market growth
                                TABLE 23 MIC STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    6.2.6.2 MIC strips market, by type
                                TABLE 24 MIC STRIPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    6.2.6.3 MIC strips market, by application
                                TABLE 25 MIC STRIPS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    6.2.6.4 MIC strips market, by method
                                TABLE 26 MIC STRIPS MARKET, BY METHOD, 2020–2027 (USD MILLION)
                    6.2.6.5 MIC strips market, by end user
                                TABLE 27 MIC STRIPS MARKET, BY END USER, 2020–2027 (USD MILLION)
           6.2.7 SUSCEPTIBILITY TESTING PLATES
                    6.2.7.1 Increasing adoption of automated/rapid AST systems hampering growth
                                TABLE 28 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    6.2.7.2 Susceptibility testing plates market, by type
                                TABLE 29 SUSCEPTIBILITY TESTING PLATES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    6.2.7.3 Susceptibility testing plates market, by application
                                TABLE 30 SUSCEPTIBILITY TESTING PLATES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    6.2.7.4 Susceptibility testing plates market, by method
                                TABLE 31 SUSCEPTIBILITY TESTING PLATES MARKET, BY METHOD, 2020–2027 (USD MILLION)
                    6.2.7.5 Susceptibility testing plates market, by end user
                                TABLE 32 SUSCEPTIBILITY TESTING PLATES MARKET, BY END USER, 2020–2027 (USD MILLION)
    6.3 AUTOMATED LABORATORY INSTRUMENTS 
           6.3.1 ONGOING TREND OF LABORATORY AUTOMATION AMONG CLINICAL LABORATORIES TO FUEL GROWTH
                    TABLE 33 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION,  2020–2027 (USD MILLION)
           6.3.2 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE
                    TABLE 34 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
           6.3.3 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION
                    TABLE 35 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
           6.3.4 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD
                    TABLE 36 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD,  2020–2027 (USD MILLION)
           6.3.5 AUTOMATED LABORATORY INSTRUMENTS MARKET,  BY END USER
                    TABLE 37 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER,  2020–2027 (USD MILLION)
    6.4 CULTURE AND GROWTH MEDIA 
           6.4.1 HIGH UTILIZATION OF DISK DIFFUSION AND BROTH DILUTION METHODS TO DRIVE GROWTH
                    TABLE 38 CULTURE AND GROWTH MEDIA MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.4.2 CULTURE AND GROWTH MEDIA MARKET, BY TYPE
                    TABLE 39 CULTURE AND GROWTH MEDIA MARKET, BY TYPE, 2020–2027 (USD MILLION)
           6.4.3 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION
                    TABLE 40 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           6.4.4 CULTURE AND GROWTH MEDIA MARKET, BY METHOD
                    TABLE 41 CULTURE AND GROWTH MEDIA MARKET, BY METHOD, 2020–2027 (USD MILLION)
           6.4.5 CULTURE AND GROWTH MEDIA MARKET, BY END USER
                    TABLE 42 CULTURE AND GROWTH MEDIA MARKET, BY END USER, 2020–2027 (USD MILLION)
    6.5 CONSUMABLES 
           6.5.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED AT HOSPITALS TO SUPPORT GROWTH
                    TABLE 43 CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.5.2 CONSUMABLES MARKET, BY TYPE
                    TABLE 44 CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
           6.5.3 CONSUMABLES MARKET, BY APPLICATION
                    TABLE 45 CONSUMABLES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           6.5.4 CONSUMABLES MARKET, BY METHOD
                    TABLE 46 CONSUMABLES MARKET, BY METHOD, 2020–2027 (USD MILLION)
           6.5.5 CONSUMABLES MARKET, BY END USER
                    TABLE 47 CONSUMABLES MARKET, BY END USER, 2020–2027 (USD MILLION)
 
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE (Page No. - 100)
    7.1 INTRODUCTION 
          TABLE 48 GLOBAL MARKET, BY TYPE, 2020–2027 (USD MILLION)
    7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING 
           7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
                    TABLE 49 ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET, BY REGION,  2020–2027 (USD MILLION)
    7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING 
           7.3.1 INCREASING INFECTIONS OF CANDIDA AND ASPERGILLUS SPECIES TO DRIVE GROWTH
                    TABLE 50 NUMBER OF HOSPITALIZATIONS AND DIRECT MEDICAL COSTS ASSOCIATED WITH FUNGAL DISEASES IN US FOR FY 2019
                    TABLE 51 ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
    7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING 
           7.4.1 RISING INITIATIVES TO CREATE AWARENESS ABOUT PARASITIC INFECTIONS TO DRIVE GROWTH
                    TABLE 52 ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET, BY REGION,  2020–2027 (USD MILLION)
    7.5 OTHER SUSCEPTIBILITY TESTING 
          TABLE 53 OTHER SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
 
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,  BY APPLICATION (Page No. - 106)
    8.1 INTRODUCTION 
          TABLE 54 GLOBAL MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
    8.2 CLINICAL DIAGNOSTICS 
           8.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED TO DRIVE GROWTH
                    TABLE 55 GLOBAL MARKET FOR CLINICAL DIAGNOSTICS,  BY REGION, 2020–2027 (USD MILLION)
    8.3 DRUG DISCOVERY AND DEVELOPMENT 
           8.3.1 RISING ADOPTION OF RAPID AST SOLUTIONS BY BIOPHARMACEUTICAL COMPANIES TO DRIVE SEGMENT GROWTH
                    TABLE 56 GLOBAL MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
    8.4 EPIDEMIOLOGY 
           8.4.1 OUTBREAK OF PANDEMICS AND EPIDEMICS TO DRIVE DEMAND FOR AST PRODUCTS
                    TABLE 57 GLOBAL MARKET FOR EPIDEMIOLOGY, BY REGION, 2020–2027 (USD MILLION)
    8.5 OTHER APPLICATIONS 
          TABLE 58 GLOBAL MARKET FOR OTHER APPLICATIONS,  BY REGION, 2020–2027 (USD MILLION)
 
9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD (Page No. - 112)
    9.1 INTRODUCTION 
          TABLE 59 GLOBAL MARKET, BY METHOD,  2020–2027 (USD MILLION)
    9.2 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING 
           9.2.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE TO DRIVE GROWTH
                    TABLE 60 AUTOMATED MARKET, BY REGION,  2020–2027 (USD MILLION)
    9.3 DISK DIFFUSION BASED SUSCEPTIBILITY TESTING
           9.3.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO DRIVE GROWTH
                    TABLE 61 DISK DIFFUSION-BASED MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.4 AGAR DILUTION BASED SUSCEPTIBILITY TESTING
           9.4.1 AGAR DILUTION HELPS EXPLORE DRUG COMBINATIONS FOR COMBINED ANTIBIOTIC THERAPY
                    TABLE 62 AGAR DILUTION-BASED MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.5 ETEST BASED SUSCEPTIBILITY TESTING
           9.5.1 UNCERTAINTIES IN RESULT INTERPRETATION AFFECTING MARKET GROWTH
                    TABLE 63 ETEST-BASED MARKET, BY REGION,  2020–2027 (USD MILLION)
    9.6 GENOTYPIC METHODS BASED SUSCEPTIBILITY TESTING
           9.6.1 ONGOING CLINICAL TRIALS AND UPCOMING PRODUCT LAUNCHES SUPPORT GROWTH
                    TABLE 64 GENOTYPIC METHODS-BASED MARKET,  BY REGION, 2020–2027 (USD MILLION)
 
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER (Page No. - 120)
     10.1 INTRODUCTION 
             TABLE 65 GLOBAL MARKET, BY END USER,  2020–2027 (USD MILLION)
     10.2 HOSPITALS AND DIAGNOSTIC CENTERS 
             10.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES AND RISING ADOPTION OF RAPID AST SOLUTIONS TO DRIVE GROWTH
                        TABLE 66 GLOBAL MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION)
     10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 
             10.3.1 INCREASING NUMBER OF BIOPHARMACEUTICAL COMPANIES TO SUPPORT SEGMENT GROWTH
                        TABLE 67 GLOBAL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
     10.4 RESEARCH AND ACADEMIC INSTITUTES 
             10.4.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH
                        TABLE 68 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020
                        TABLE 69 GLOBAL MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
     10.5 CONTRACT RESEARCH ORGANIZATIONS 
             10.5.1 CLINICAL TRIAL GLOBALIZATION AND GROWING NUMBER OF CROS IN EMERGING ECONOMIES TO DRIVE GROWTH
                        TABLE 70 GLOBAL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
 
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION (Page No. - 126)
     11.1 INTRODUCTION 
             TABLE 71 GLOBAL MARKET, BY REGION,  2020–2027 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 26 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
             TABLE 72 NORTH AMERICA: MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
             TABLE 73 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 74 NORTH AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 75 NORTH AMERICA: MARKET, BY TYPE,  2020–2027 (USD MILLION)
             TABLE 76 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 77 NORTH AMERICA: MARKET, BY METHOD, 2020–2027 (USD MILLION)
             TABLE 78 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US to dominate North American market during forecast period
                                      TABLE 79 US: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 80 US: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Favorable government initiatives to drive growth during forecast period
                                      TABLE 81 CANADA: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 82 CANADA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
     11.3 EUROPE 
             TABLE 83 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
             TABLE 84 EUROPE: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
             TABLE 85 EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
             TABLE 86 EUROPE: MARKET, BY TYPE,  2020–2027 (USD MILLION)
             TABLE 87 EUROPE: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
             TABLE 88 EUROPE: MARKET, BY METHOD,  2020–2027 (USD MILLION)
             TABLE 89 EUROPE: MARKET, BY END USER,  2020–2027 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Germany to dominate European market during forecast period
                                      TABLE 90 GERMANY: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 91 GERMANY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 Supportive government policies and easy access to healthcare services to fuel growth
                                      TABLE 92 FRANCE: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 93 FRANCE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Significant prevalence of infectious diseases coupled with increasing awareness of AST products to drive market growth
                                      TABLE 94 UK: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 95 UK: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand for AST products
                                      TABLE 96 ITALY: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 97 ITALY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Rising geriatric population to drive market growth
                                      TABLE 98 SPAIN: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 99 SPAIN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 100 REST OF EUROPE: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                        TABLE 101 REST OF EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
     11.4 ASIA PACIFIC 
             FIGURE 27 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
             TABLE 102 ASIA PACIFIC: MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
             TABLE 103 ASIA PACIFIC: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
             TABLE 104 ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 105 ASIA PACIFIC: MARKET, BY TYPE,  2020–2027 (USD MILLION)
             TABLE 106 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 107 ASIA PACIFIC: MARKET, BY METHOD,  2020–2027 (USD MILLION)
             TABLE 108 ASIA PACIFIC: MARKET, BY END USER,  2020–2027 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Growing geriatric population to drive market
                                      TABLE 109 JAPAN: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 110 JAPAN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth
                                      TABLE 111 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020
                                      TABLE 112 CHINA: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 113 CHINA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth
                                      TABLE 114 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 115 INDIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Increasing government funding for research activities to drive market growth
                                      TABLE 116 AUSTRALIA: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 117 AUSTRALIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Requirement of rapid AMR detection to drive growth
                                      TABLE 118 SOUTH KOREA: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 119 SOUTH KOREA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 120 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 121 REST OF ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
     11.5 LATIN AMERICA 
             TABLE 122 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 123 LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 124 LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 125 LATIN AMERICA: MARKET, BY TYPE,  2020–2027 (USD MILLION)
             TABLE 126 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 127 LATIN AMERICA: MARKET, BY METHOD,  2020–2027 (USD MILLION)
             TABLE 128 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Established presence of major AST product manufacturers to drive growth
                                      TABLE 129 BRAZIL: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 130 BRAZIL: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Growing economic development to drive market growth
                                      TABLE 131 MEXICO: MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                                      TABLE 132 MEXICO: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET,  BY TYPE, 2020–2027 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 133 REST OF LATIN AMERICA: MARKET,  BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 134 REST OF LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH
                        TABLE 135 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,  BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 136 MIDDLE EAST & AFRICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 137 MIDDLE EAST & AFRICA: MARKET, BY TYPE,  2020–2027 (USD MILLION)
                        TABLE 138 MIDDLE EAST & AFRICA: MARKET,  BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 139 MIDDLE EAST & AFRICA: MARKET, BY METHOD, 2020–2027 (USD MILLION)
                        TABLE 140 MIDDLE EAST & AFRICA: MARKET,  BY END USER, 2020–2027 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 171)
     12.1 INTRODUCTION 
     12.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN 
             TABLE 141 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GLOBAL MARKET
     12.4 MARKET SHARE ANALYSIS (2021) 
             FIGURE 29 BIOMÉRIEUX SA HELD LEADING POSITION IN GLOBAL MARKET IN 2021
     12.5 COMPANY EVALUATION MATRIX FOR 25 MAJOR PLAYERS (2021) 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 30 GLOBAL MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2021
     12.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021) 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 31 GLOBAL MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2021
     12.7 COMPETITIVE BENCHMARKING 
             TABLE 142 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN GLOBAL MARKET
             TABLE 143 APPLICATION FOOTPRINT ANALYSIS OF TOP PLAYERS IN GLOBAL MARKET
             TABLE 144 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN GLOBAL MARKET
     12.8 COMPETITIVE SCENARIO 
             12.8.1 PRODUCT LAUNCHES
                        TABLE 145 GLOBAL MARKET: PRODUCT LAUNCHES, JANUARY 2020–JANUARY 2023
             12.8.2 DEALS
                        TABLE 146 GLOBAL MARKET: DEALS,  JANUARY 2020–JANUARY 2023
 
13 COMPANY PROFILES (Page No. - 186)
(Business overview, Products offered, Recent Developments, MNM view)*
     13.1 KEY PLAYERS 
             13.1.1 BIOMÉRIEUX SA
                        TABLE 147 COMPANY OVERVIEW: BIOMÉRIEUX SA
                        FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT
             13.1.2 BECTON, DICKINSON AND COMPANY
                        TABLE 148 COMPANY OVERVIEW: BECTON, DICKINSON AND COMPANY
                        FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
             13.1.3 THERMO FISHER SCIENTIFIC
                        TABLE 149 COMPANY OVERVIEW: THERMO FISHER SCIENTIFIC
                        FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
             13.1.4 DANAHER CORPORATION
                        TABLE 150 COMPANY OVERVIEW: DANAHER CORPORATION
                        FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT
             13.1.5 BIO-RAD LABORATORIES, INC.
                        TABLE 151 COMPANY OVERVIEW: BIO-RAD LABORATORIES, INC.
                        FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
             13.1.6 BRUKER
                        TABLE 152 COMPANY OVERVIEW: BRUKER
                        FIGURE 37 BRUKER: COMPANY SNAPSHOT
             13.1.7 ROCHE DIAGNOSTICS
                        TABLE 153 COMPANY OVERVIEW: ROCHE DIAGNOSTICS
                        FIGURE 38 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
             13.1.8 MERCK KGAA
                        TABLE 154 COMPANY OVERVIEW: MERCK KGAA
                        FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
             13.1.9 ACCELERATE DIAGNOSTICS, INC.
                        TABLE 155 COMPANY OVERVIEW: ACCELERATE DIAGNOSTICS, INC.                        
                        FIGURE 40 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT
             13.1.10 HIMEDIA LABORATORIES
                        TABLE 156 COMPANY OVERVIEW: HIMEDIA LABORATORIES
             13.1.11 LIOFILCHEM S.R.L.
                        TABLE 157 COMPANY OVERVIEW: LIOFILCHEM S.R.L.
             13.1.12 ALIFAX S.R.L.
                        TABLE 158 COMPANY OVERVIEW: ALIFAX S.R.L.
             13.1.13 CREATIVE DIAGNOSTICS
                        TABLE 159 COMPANY OVERVIEW: CREATIVE DIAGNOSTICS
             13.1.14 SYNBIOSIS
                        TABLE 160 COMPANY OVERVIEW: SYNBIOSIS
             13.1.15 BIOANALYSE
                        TABLE 161 COMPANY OVERVIEW: BIOANALYSE
     13.2 OTHER COMPANIES 
             13.2.1 ZHUHAI DL BIOTECH CO., LTD.
             13.2.2 ELITECH GROUP
             13.2.3 MAST GROUP LTD.
             13.2.4 CONDALAB
             13.2.5 GENEFLUIDICS, INC.
             13.2.6 BIOTRON LTD.
             13.2.7 INVIVOGEN
             13.2.8 MP BIOMEDICALS
             13.2.9 QUANTAMATRIX INC.
             13.2.10 PML MICROBIOLOGICALS
 
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 235)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microcatheter market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the medical aesthetic market. The primary sources from the demand side include medical OEMs, Oncologists, CDMOs and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Antimicrobial Susceptibility Testing Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the antimicrobial susceptibility testing market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the medical aesthetic business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • Generating a list of major global players operating in the microcatheter market.
  • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
  • Revenue mapping of major players to cover major share of the global market share, as of 2021
  • Extrapolating the global value of the antimicrobial susceptibility testing market

Antimicrobial Susceptibility Testing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the Antimicrobial susceptibiity testing marketwas split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the antimicrobial susceptibility testing market was validated using both top-down and bottom-up approaches.

Objectives of the Study

  • To define, describe, and forecast the Antimicrobial susceptibility testing market on the basis of product, type, method, applications ,end user, and region .
  • To provide detailed information regarding the major factors influencing the growth potential of the Antimicrobial susceptibiity testing market(drivers, restraints, opportunities, challenges, and trends)
  • To analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the Antimicrobial susceptibiity testing market
  • To analyze key growth opportunities in the Antimicrobial susceptibiity testing market for key stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Thailand, Indonesia and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
  • To profile the key players in the Antimicrobial susceptibiity testing marketand comprehensively analyze their market shares and core competencies
  • To track and analyze the competitive developments undertaken in the Antimicrobial susceptibility testing market, such as product launches; agreements; expansions; and mergers & acquisitions

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global microcatheter report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe Antimicrobial susceptibility testing market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of the Asia Pacific Antimicrobial susceptibility testing market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Latin American Antimicrobial susceptibility testing market into Colombia, Chile, Argentina, and Peru, among other
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 5931
Published ON
Feb, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Antimicrobial Susceptibility Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback